University Clinic, Kantonsspital Aarau
Aarau, Canton of Aargau, 5000, Switzerland
NCT Number: NCT02517476
The aims of the randomized-controlled, multicenter EFFORT trial are to assess the effects of early nutritional therapy in regard to effectiveness, safety and costs when applied to the heterogenous, polymorbid medical inpatient population. EFFORT will not only answer the question about overall benefit or harm, but using a physio-pathological mechanistic approach, it also will explore and provide conclusive answers about whether, why, how, and in which patient populations nutritional therapy does and does not works.
Looking for future studies?
Notify Me16 year and older
All sexes
Interventional
Phase 4
Aarau, Canton of Aargau, 5000, Switzerland
The aims of the randomized-controlled, multicenter EFFORT trial are to test the hypothesis that in medical inpatients at risk for undernutrition defined by the nutritional risk score (NRS 2002), early tailored nutritional therapy to reach nutritional targets based on individualized nutritional counseling is a cost-effective strategy to prevent mortality, morbidity and functional decline.
The primary composite endpoint is combined adverse outcome within 30 days defined as (a) all-cause mortality, (b) admission to the intensive care unit from the medical ward, (c) major complications, (d) unplanned hospital readmissions and (d) decline in functional outcome from admission to day 30 assessed by Barthel's index (-10%). Secondary endpoints include (a) each single component of the primary endpoint (b) short-term nutritional and functional outcomes from inclusion to day 10 or hospital discharge; (c) hospital outcomes; (d) 30-day and 180-day outcomes (e) Other safety endpoints including adverse gastrointestinal effects associated with nutritional therapy assessed daily until hospital discharge.
The investigators will include unselected adult medical inpatients at risk of undernutrition [NRS≥3 points] and an expected hospital stay of ≥5 days who are willing to provide informed consent. The investigators will exclude patients in critical care or post-operative state, unable to swallow, at long-term need for parenteral/enteral nutrition, in terminal condition, pregnant, with acute pancreatitis or acute liver failure, with anorexia nervosa, that were earlier included into the trial Patients in the intervention group will receive individualized nutritional therapy to reach nutritional targets (caloric, protein, micronutrients, other) based on a predefined nutritional strategy. In control patients, according to patients' appetite, standard hospital nutrition will be served. Nutritional therapy may be started in control patients, if any sort of swallowing disorders develops or if patients need to be prepared for operation. All patients will be re-assessed daily during the hospital stay for nutritional intake and nutritional therapy may be escalated every 24-48 hours (food fortification, oral supplements, enteral, parenteral nutrition) if targets are not met (at least 75% of targets).
The targeted sample size is 2000 - 3000 patients. The inclusion of 2000 - 3000 patients will provide between 76% and 91% power to detect a reduction in the primary endpoint of 15% (from 40% to 34%) assuming a lost to follow up rate of 10%.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
Time frame: measured at day 30 by telephone interview
Number of participants with adverse events including
Time frame: measured at day 30 by telephone interview
change in weight and BMI from inclusion to day 30 by patient interview and medical chart review
Time frame: participants will be followed for the duration of hospital stay with an expected average of 10 days
days in the hospital within index hospitalisation and within the 30 days of follow up measured by patient interview and medical chart review
Time frame: measured at days 30 and 180 by telephone interview
Improvement in quality of life measured with the EuroQol Group 5-Dimension Self-Report Questionnaire on admission and during follow up measured by patient interview
Time frame: measured at day 30
Number of participants with side effects from nutritional therapy including
(a) adverse gastrointestinal effects (diarrhea, nausea, vomiting, abdominal pain) assessed by patient interview (yes/no) b) Complications due to tube feeding or center catheter for parenteral nutrition assessed by medical chart review (c) Refeeding syndrome assessed by chart review (d) Acute pancreatitis defined as 2 out of 3 criteria: abdominal pain, 3-fold increase in lipase or amylase, characteristic imaging findings assessed by chart review (e) Liver or gall bladder dysfunction assessed by chart review (f) Hyperglycemia (defined as glucose levels >12mmol/l or persistent levels >10mmol/l in patients without diabetes or well controlled diabetes) assessed by medical chart review
Time frame: assessed on the day of hospital discharge after an expected average of 10 days
Clinical diagnosis of decubital ulcer with onset after study inclusion measured by patient interview and medical chart review
Time frame: assessed on the day of hospital discharge after an expected average of 10 days
proportion discharge home or to a rehab facility measured by patient interview and medical chart review
University Hospital, Basel, Switzerland
Other
Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial: The EFFORT Trial
Acronym: EFFORT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02911246
Brain Diseases, Brain Injuries
Nantes, France
View Trial DetailsNCT06397118
Anemia, Anemia, Hemolytic
Nashville, Tennessee, United States
View Trial DetailsNCT04244851
Malnutrition, Nutrition Disorders
Rennes, France
View Trial DetailsNCT07620197
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Kisumu, Kenya
View Trial Details